C4 TherapeuticsInc Correlations
| CCCC Stock | USD 6.26 0.09 1.46% |
The correlation of C4 TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as C4 TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if C4 TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Very weak diversification
The correlation between C4 TherapeuticsInc and NYA is 0.41 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding C4 TherapeuticsInc and NYA in the same portfolio, assuming nothing else is changed.
CCCC |
The ability to find closely correlated positions to C4 TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace C4 TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back C4 TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling C4 TherapeuticsInc to buy it.
Moving together with CCCC Stock
| 0.73 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.61 | BHC | Bausch Health Companies Financial Report 2nd of May 2024 | PairCorr |
| 0.69 | BMY | Bristol Myers Squibb | PairCorr |
| 0.84 | EBS | Emergent Biosolutions Financial Report 14th of May 2024 | PairCorr |
Moving against CCCC Stock
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between CCCC Stock performing well and C4 TherapeuticsInc Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze C4 TherapeuticsInc's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| STTK | 3.17 | 0.09 | 0.03 | 0.15 | 3.25 | 8.44 | 19.00 | |||
| ELYM | 4.11 | 0.84 | 0.17 | (1.00) | 3.21 | 10.21 | 79.43 | |||
| PRLD | 4.62 | 0.47 | 0.08 | 0.29 | 5.71 | 8.44 | 50.75 | |||
| GLUE | 5.07 | (0.07) | 0.01 | 0.06 | 7.04 | 10.84 | 38.28 | |||
| FHTX | 6.11 | 1.01 | 0.20 | 0.35 | 5.23 | 22.68 | 69.93 | |||
| CYT | 0.70 | (0.04) | 0.00 | (0.25) | 0.00 | 1.64 | 4.87 | |||
| RZLT | 5.00 | 1.46 | 0.22 | 1.31 | 5.48 | 12.17 | 33.28 | |||
| IPSC | 4.74 | (0.68) | 0.00 | (0.10) | 0.00 | 8.37 | 32.09 | |||
| EWTX | 2.69 | (0.03) | 0.02 | 0.06 | 3.21 | 5.79 | 18.27 | |||
| MLYS | 2.89 | 0.13 | 0.08 | 0.13 | 3.09 | 6.90 | 26.82 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in C4 TherapeuticsInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
C4 TherapeuticsInc Corporate Management
Elected by the shareholders, the C4 TherapeuticsInc's board of directors comprises two types of representatives: C4 TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CCCC. The board's role is to monitor C4 TherapeuticsInc's management team and ensure that shareholders' interests are well served. C4 TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, C4 TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kendra Adams | Chief Officer | Profile | |
| Kelly Schick | Chief Officer | Profile | |
| Isabel Chiu | Senior Development | Profile | |
| Mr MBA | Chief Officer | Profile | |
| Andrew Hirsch | Pres CEO | Profile | |
| Jolie JD | Chief Secretary | Profile |
Already Invested in C4 TherapeuticsInc?
The danger of trading C4 TherapeuticsInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of C4 TherapeuticsInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than C4 TherapeuticsInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile C4 TherapeuticsInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether C4 TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeuticsinc Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.Note that the C4 TherapeuticsInc information on this page should be used as a complementary analysis to other C4 TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for CCCC Stock analysis
When running C4 TherapeuticsInc's price analysis, check to measure C4 TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 TherapeuticsInc is operating at the current time. Most of C4 TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of C4 TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 TherapeuticsInc's price. Additionally, you may evaluate how the addition of C4 TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is C4 TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 TherapeuticsInc. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.67) | Revenue Per Share 0.418 | Quarterly Revenue Growth 0.143 | Return On Assets (0.22) | Return On Equity (0.49) |
The market value of C4 TherapeuticsInc is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is C4 TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 TherapeuticsInc's market value can be influenced by many factors that don't directly affect C4 TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.